Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] ISU PETASYS (007660) – Report on Reasons for Holding Annual General Meeting on Concentrated Date / 2024-03-14

Posted on March 14, 2024August 1, 2026 By K-STOCK Editor No Comments on [Disclosure] ISU PETASYS (007660) – Report on Reasons for Holding Annual General Meeting on Concentrated Date / 2024-03-14

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

ISU PETASYS disclosed that due to the financial closing and audit schedules of overseas subsidiaries, it is holding its 2024 Annual General Meeting on March 29, 2024, a date expected to have a high concentration of AGMs.

📊 [Key Disclosure Details & Financial Summary]

  1. Company Name: ISU PETASYS Co., Ltd.
  2. Date of AGM (Scheduled): March 29, 2024 (Friday)
  3. Reason for Holding AGM on Concentrated Date:
  • The company attempted to avoid concentrated AGM dates, but holding the meeting on March 29, 2024, was unavoidable due to the closing schedules of consolidated subsidiaries (especially overseas entities) and the timeline required for consolidated financial statement preparation and auditing.
  1. Date of Notice/Announcement of AGM: March 14, 2024
  2. Other Key Matters:
  • Non-participant in the voluntary AGM Date Diversification Program organized by the Korea Listed Companies Association.
  • Expected concentrated AGM dates announced by the association: March 22 (Fri), March 28 (Thu), and March 29 (Fri), 2024.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Reasons for Holding AGM on Concentrated Date and Verification of Meeting Procedures

The company stated that its AGM date was scheduled on a concentrated date due to financial closing and audit timelines for overseas subsidiaries. Reviewing the reason and schedule is important to understand the background of the meeting timing. Relevant details can be tracked through the AGM Results disclosure following the meeting.

📢 Disclaimer & Source Notice

Source: This content has been newly structured and created based on official filing data from the Financial Supervisory Service DART system.

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific securities. All investment decisions and financial liabilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] HPSP (403870) – Report on Reason for Holding General Meeting of Shareholders on Concentrated Date / 2024-03-14
Next Post: [Disclosure] Hana Micron (067310) – Decision on Debt Guarantee for Others / 2024-03-14

Related Posts

[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Application for CT-P13 SC (Remsima Subcutaneous) in Pediatric Ulcerative Colitis in Korea / 2025-02-24 Disclosures
[Disclosure] Hanwha Ocean (042660) – (Correction) Sales and Supply Contract / 2025-06-05 Disclosures
[Disclosure] SK hynix (000660) – Decision on Disposal of Treasury Shares / 2025-10-29 Semiconductors
[Disclosure] Celltrion (068270) – CT-P55 (Cosentyx Biosimilar) Korea Marketing Authorization Application / 2026-06-26 Disclosures
[Disclosure] Hanwha Aerospace (012450) Sets Record Date (December 31, 2024) for 48th Annual General Meeting of Shareholders Disclosures
[Disclosure] ISU PETASYS (007660) – Setting of Record Date or Closing Period of Shareholder Register (Correction) / 2024-12-11 Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme